



**Telix Pharmaceuticals Limited**

ACN 616 620 369  
55 Flemington Road  
North Melbourne  
Victoria, 3051  
Australia

**ASX RELEASE**

## **Telix Urology Innovation Showcase**

**June 21, 2023, at The Yale Club, New York City**

*Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 21 June 2023.* Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an outline agenda for the Company's briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am EDT (10.30pm AEST) and via live webcast.<sup>1</sup> The briefing session will provide an opportunity for shareholders to hear from the Company in relation to its recent market disclosures<sup>2</sup> and will focus on:

- Telix's vision for the field of urology
- The commercialisation of Telix's lead product Illuccix® for prostate cancer imaging
- The Company's pipeline in urologic oncology, including current clinical activity.

The briefing will also feature key opinion leaders' perspectives on the clinical utility of the Company's investigational products TLX250-CDx for renal cancer imaging and TLX591 for prostate cancer therapy.

Briefing session agenda:

- Dr. Christian Behrenbruch (CEO and Group Managing Director) will provide an overview of the Company's growth strategy in urologic oncology
- Kevin Richardson (CEO Telix Americas) will present on how Telix has built its commercial organisation to meet the needs of the urologic customer base
- Dr. Colin Hayward (Chief Medical Officer) will discuss published clinical and scientific evidence supporting the expanded utility of prostate-specific membrane antigen (PSMA) imaging and the scientific rationale for the Company's carbonic anhydrase IX (CAIX) program in renal cancer therapy and current clinical programs
- Brian Shuch, MD, Director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at UCLA will detail the results of the Company's Phase III ZIRCON study and a clinician's perspective on the potential utility of the imaging candidate
- Scott T. Tagawa, MD, MS, FACP, Professor of Medicine and Urology will discuss clinical and scientific insights into the Company's TLX591 program for prostate cancer therapy.

Shareholders wishing to attend this briefing session in person are required to register their attendance through this [link](#).

The briefing session will also be broadcast live via webcast for shareholders who cannot attend in person. Please register at this [link](#) for the live webcast.

A recording of the event will also be made available on the Company's website.

---

<sup>1</sup> Telix media release 25 May 2023.

<sup>2</sup> Telix ASX disclosures 17 April, 27 April, 1 May, 24 May and 19 June 2023.

---

## About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit [www.telixpharma.com](http://www.telixpharma.com) for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on [Twitter \(@TelixPharma\)](https://twitter.com/TelixPharma) and [LinkedIn](https://www.linkedin.com/company/telix-pharmaceuticals-limited).

TLX250-CDx and TLX591 have not received a marketing authorisation in any jurisdiction. Telix's lead product, gallium-68 (<sup>68</sup>Ga) gozetotide (also known as <sup>68</sup>Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),<sup>3</sup> and by the Australian Therapeutic Goods Administration (TGA),<sup>4</sup> and by Health Canada.<sup>5</sup> Telix is also progressing a marketing authorisation application for this investigational candidate in the United Kingdom and the European Union.<sup>6</sup>

## Telix Investor Relations

Ms. Kyahn Williamson  
Telix Pharmaceuticals Limited  
SVP Corporate Communications and Investor Relations  
Email: [kyahn.williamson@telixpharma.com](mailto:kyahn.williamson@telixpharma.com)

Lisa Wilson  
In-Site Communications  
Email: [lwilson@insitecony.com](mailto:lwilson@insitecony.com)

*This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.*

## Legal Notices

*This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.*

---

<sup>3</sup> Telix ASX disclosure 20 December 2021.

<sup>4</sup> Telix ASX disclosure 2 November 2021.

<sup>5</sup> Telix ASX disclosure 14 October 2022.

<sup>6</sup> Telix ASX disclosure 3 April 2023.

---

*Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website.*

*©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).*